BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 80.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 97,793 shares of the biotechnology company’s stock after buying an additional 43,556 shares during the quarter. Intech Investment Management LLC’s holdings in BioCryst Pharmaceuticals were worth $735,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of BioCryst Pharmaceuticals by 2.7% during the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after purchasing an additional 127,708 shares in the last quarter. Fisher Asset Management LLC grew its stake in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after buying an additional 481,359 shares during the last quarter. Two Sigma Advisers LP increased its position in BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after buying an additional 261,500 shares during the period. FMR LLC lifted its stake in BioCryst Pharmaceuticals by 2.4% in the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after buying an additional 46,110 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after acquiring an additional 91,998 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Up 3.8 %

NASDAQ BCRX opened at $7.98 on Monday. The stock has a market capitalization of $1.67 billion, a P/E ratio of -13.08 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50. The firm has a 50-day moving average price of $8.12 and a 200 day moving average price of $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.28 EPS. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.